191 related articles for article (PubMed ID: 31700585)
1. The Course of Hepatitis C Infection and Response to Anti-viral Therapy in Patients with Thalassemia major and Hepatitis C Infection: A Longitudinal, Prospective Study.
Kamal S; Abdelhakam S; Ghoraba D; Mohsen MA; Salam AA; Hassan H; Nabeigh L
Mediterr J Hematol Infect Dis; 2019; 11(1):e2019060. PubMed ID: 31700585
[TBL] [Abstract][Full Text] [Related]
2. Liver fibrosis in young Egyptian beta-thalassemia major patients: relation to hepatitis C virus and compliance with chelation.
Elalfy MS; Esmat G; Matter RM; Abdel Aziz HE; Massoud WA
Ann Hepatol; 2013; 12(1):54-61. PubMed ID: 23293194
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection in Patients with β-Thalassemia Major.
Mehta R; Kabrawala M; Nandwani S; Desai P; Bhayani V; Patel S; Parekh V
J Clin Exp Hepatol; 2018 Mar; 8(1):3-6. PubMed ID: 29743790
[TBL] [Abstract][Full Text] [Related]
4. Progression of liver fibrosis can be controlled by adequate chelation in transfusion-dependent thalassemia (TDT).
Maira D; Cassinerio E; Marcon A; Mancarella M; Fraquelli M; Pedrotti P; Cappellini MD
Ann Hematol; 2017 Nov; 96(11):1931-1936. PubMed ID: 28875336
[TBL] [Abstract][Full Text] [Related]
5. Impact of the direct-acting antiviral agents (DAAs) on chronic hepatitis C in Sardinian patients with transfusion-dependent Thalassemia major.
Ponti ML; Comitini F; Murgia D; Ganga R; Canu R; Dessì C; Foschini ML; Leoni G; Morittu M; Perra M; Pilia MP; Casini MR; Zappu A; Origa R
Dig Liver Dis; 2019 Apr; 51(4):561-567. PubMed ID: 30658940
[TBL] [Abstract][Full Text] [Related]
6. Direct acting antivirals are associated with more liver stiffness regression than pegylated interferon therapy in chronic hepatitis C patients.
Abdelsameea E; Alsebaey A; Abdel-Samiee M; Abdel-Razek W; Salama M; Waked I
Expert Rev Anti Infect Ther; 2021 Aug; 19(8):1053-1059. PubMed ID: 33307880
[TBL] [Abstract][Full Text] [Related]
7. The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C.
Liang PC; Lin PC; Huang CI; Huang CF; Yeh ML; Zeng YS; Hsu WY; Hsieh MY; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Chiou SS; Yu ML
J Formos Med Assoc; 2018 Jan; 117(1):14-23. PubMed ID: 29097076
[TBL] [Abstract][Full Text] [Related]
8. Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?
Kronfli N; Young J; Wang S; Cox J; Walmsley S; Hull M; Cooper C; Martel-Laferriere V; Wong A; Pick N; Klein MB;
Clin Infect Dis; 2021 Aug; 73(3):468-477. PubMed ID: 32504083
[TBL] [Abstract][Full Text] [Related]
9. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
10. Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies.
Origa R; Ponti ML; Filosa A; Galeota Lanza A; Piga A; Saracco GM; Pinto V; Picciotto A; Rigano P; Madonia S; Rosso R; D'Ascola D; Cappellini MD; D'Ambrosio R; Tartaglione I; De Franceschi L; Gianesin B; Di Marco V; Forni GL;
Am J Hematol; 2017 Dec; 92(12):1349-1355. PubMed ID: 28929515
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response.
D'Ambrosio R; Aghemo A; Fraquelli M; Rumi MG; Donato MF; Paradis V; Bedossa P; Colombo M
J Hepatol; 2013 Aug; 59(2):251-6. PubMed ID: 23528378
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive Assessment of Liver Fibrosis By Transient Elastography and FIB4/APRI for Prediction of Treatment Response in Chronic Hepatitis C-An Experience from a Tertiary Care Hospital.
Taneja S; Tohra S; Duseja A; Dhiman RK; Chawla YK
J Clin Exp Hepatol; 2016 Dec; 6(4):282-290. PubMed ID: 28003717
[TBL] [Abstract][Full Text] [Related]
13. Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study.
Soliman H; Ziada D; Salama M; Hamisa M; Badawi R; Hawash N; Selim A; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2020; 20(1):104-111. PubMed ID: 31448717
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of
Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
[TBL] [Abstract][Full Text] [Related]
15. Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis.
Tmu N; Kumar A; Sharma P; Singla V; Bansal N; Arora A
J Clin Exp Hepatol; 2019; 9(1):4-12. PubMed ID: 30765933
[TBL] [Abstract][Full Text] [Related]
16. Correlation Between Serum Ferritin and Viral Hepatitis in Thalassemia Patients.
Rujeerapaiboon N; Tantiworawit A; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Rattarittamrong E; Norasetthada L; Fanhchaksai K; Charoenkwan P
Hemoglobin; 2021 May; 45(3):175-179. PubMed ID: 34121572
[TBL] [Abstract][Full Text] [Related]
17. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
[TBL] [Abstract][Full Text] [Related]
18. Serum YKL-40 in young patients with β-thalassemia major: Relation to hepatitis C virus infection, liver stiffness by transient elastography and cardiovascular complications.
El-Asrar MA; Elbarbary NS; Ismail EA; Elshenity AM
Blood Cells Mol Dis; 2016 Jan; 56(1):1-8. PubMed ID: 26603717
[TBL] [Abstract][Full Text] [Related]
19. Therapy for treatment-refractory chronic hepatitis C virus genotype 1b infection: A retrospective analysis.
Cindoruk M; Karakan T; Unal S
Curr Ther Res Clin Exp; 2005 Sep; 66(5):451-62. PubMed ID: 24790245
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
